LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
9 hedge funds and large institutions have $3.79M invested in LakeShore Biopharma in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.72% less ownership
Funds ownership: 1.01% → 0.29% (-0.72%)
10% less funds holding
Funds holding: 10 → 9 (-1)
22% less capital invested
Capital invested by funds: $4.89M → $3.79M (-$1.1M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$867K |
| 2 |
VAM
Valliance Asset Management
Central,
Hong Kong
|
-$821K |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$508K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$23.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $1.1M | -$867K | -170,188 | -53% |
|
|
2
Fidelity International
Hamilton,
Bermuda
| $843K | -$508K | -99,757 | -45% |
|
3
Fidelity Investments
Boston,
Massachusetts
| $816K | – | – | – |
|
|
HA
4
HHLR Advisors
Grand Cayman,
Cayman Islands
| $526K | – | – | – |
|
|
5
Bank of Montreal
Toronto,
Ontario, Canada
| $275K | +$175K | +34,412 | New |
|
|
SCM
6
Superstring Capital Management
New York
| $216K | – | – | – |
|
7
Geode Capital Management
Boston,
Massachusetts
| $9.53K | – | – | – |
|
|
PAM
8
Pinpoint Asset Management
Hong Kong
| $3.58K | – | – | – |
|
|
WAM
9
Wolverine Asset Management
Chicago,
Illinois
| $359 | – | – | – |
|
|
VAM
10
Valliance Asset Management
Central,
Hong Kong
| – | -$821K | -160,718 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$23.1K | -4,286 | Closed |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$2 | – | – |
|
LSB Hedge Fund Activity: Q1 2024 in Review
9 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q1 2024, worth a combined $3.79M — down 22% from $4.89M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LSB and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $175K. The largest seller was OrbiMed, cutting an estimated $867K.
- 9 institutional investors held LakeShore Biopharma (LSB) as of Q1 2024, down from 10 in Q4 2023.
- Funds reported $3.79M of LakeShore Biopharma stock for Q1 2024, down 22% quarter-over-quarter.
- 1 fund opened new LakeShore Biopharma positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest LakeShore Biopharma buyer in Q1 2024 was Bank of Montreal, an estimated $175K added.
- The largest LakeShore Biopharma seller in Q1 2024 was OrbiMed, an estimated $867K sold.
Based on aggregated 13F filings for Q1 2024.